⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer

Official Title: A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer (DTC)

Study ID: NCT04940052

Study Description

Brief Summary: 150 adults patients with locally advanced or metastatic BRAFV600E mutation-positive, differentiated thyroid carcinoma who are refractory to radioactive iodine and have progressed following prior VEGFR targeted therapy will enter in the trial. Patients will be randomized in a 2:1 ratio to either dabrafenib plus trametinib or placebo. Patients will be stratified by number of prior VEGFR targeted therapy (1versus2) and prior lenvatinib treatment (yes versus no)

Detailed Description: This is a global, multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of dabrafenib plus trametinib in adult patients with locally advanced or metastatic BRAFV600E mutation-positive, differentiated thyroid cancer who are refractory to radioactive iodine and have progressed following prior VEGFR targeted therapy. After eligibility assessment, approximately 150 patients will be randomized in a 2:1 ratio to either dabrafenib plus trametinib or placebo. Patients will receive dabrafenib in combination with trametinib or placebo until disease progression as per RECIST 1.1 as determined by investigator and confirmed by BIRC or loss of clinical benefit as determined by investigator, death, unacceptable toxicity, pregnancy, withdrawal of consent, lost to follow-up or early termination of the study by the sponsor. Patients randomized in the placebo arm and for whom progression as per RECIST 1.1 is confirmed by blinded independent review committee and who meet the criteria will be given the option to cross over to the open label combination drug dabrafenib plus trametinib

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Northwestern University Med School, Chicago, Illinois, United States

Massachusetts General Hospital Dept of MGH 2, Boston, Massachusetts, United States

Novartis Investigative Site, Caba, Buenos Aires, Argentina

Novartis Investigative Site, Buenos Aires, , Argentina

Novartis Investigative Site, Rio De Janiero, RJ, Brazil

Novartis Investigative Site, Porto Alegre, RS, Brazil

Novartis Investigative Site, Blumenau, Santa Catarina, Brazil

Novartis Investigative Site, Sao Paulo, SP, Brazil

Novartis Investigative Site, Sao Paulo, , Brazil

Novartis Investigative Site, Calgary, Alberta, Canada

Novartis Investigative Site, Edmonton, Alberta, Canada

Novartis Investigative Site, London, Ontario, Canada

Novartis Investigative Site, Toronto, Ontario, Canada

Novartis Investigative Site, Fuzhou, Fujian, China

Novartis Investigative Site, Zhengzhou, Henan, China

Novartis Investigative Site, Wuhan, Hubei, China

Novartis Investigative Site, Nanjing, Jiangsu, China

Novartis Investigative Site, Nanjing, Jiangsu, China

Novartis Investigative Site, Xuzhou, Jiangsu, China

Novartis Investigative Site, Changchun, Jilin, China

Novartis Investigative Site, XI An, Shanxi, China

Novartis Investigative Site, Xi'an, Shanxi, China

Novartis Investigative Site, Chengdu, Sichuan, China

Novartis Investigative Site, Tianjin, Tianjin, China

Novartis Investigative Site, Kunming City, Yunnan, China

Novartis Investigative Site, Hangzhou, Zhejiang, China

Novartis Investigative Site, Beijing, , China

Novartis Investigative Site, Beijing, , China

Novartis Investigative Site, Changsha, , China

Novartis Investigative Site, Guangzhou, , China

Novartis Investigative Site, Shanghai, , China

Novartis Investigative Site, Tianjin, , China

Novartis Investigative Site, Tianjin, , China

Novartis Investigative Site, Hisar, Haryana, India

Novartis Investigative Site, Mumbai, Maharashtra, India

Novartis Investigative Site, Vellore, Tamil Nadu, India

Novartis Investigative Site, Hyderabad, Telangana, India

Novartis Investigative Site, Chennai, , India

Novartis Investigative Site, New Delhi, , India

Novartis Investigative Site, Seoul, Seocho Gu, Korea, Republic of

Novartis Investigative Site, Seoul, , Korea, Republic of

Novartis Investigative Site, Seoul, , Korea, Republic of

Novartis Investigative Site, Seoul, , Korea, Republic of

Novartis Investigative Site, Kuching, Sarawak, Malaysia

Novartis Investigative Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia

Novartis Investigative Site, Kuala Lumpur, , Malaysia

Novartis Investigative Site, Kuala Lumpur, , Malaysia

Novartis Investigative Site, Pulau Pinang, , Malaysia

Novartis Investigative Site, Ciudad de Mexico, Mexico CP, Mexico

Novartis Investigative Site, Monterrey, Nuevo Leon, Mexico

Novartis Investigative Site, Chihuahua, , Mexico

Novartis Investigative Site, Tainan, , Taiwan

Novartis Investigative Site, Taipei, , Taiwan

Novartis Investigative Site, Istanbul, TUR, Turkey

Novartis Investigative Site, Adana, , Turkey

Novartis Investigative Site, Ankara, , Turkey

Novartis Investigative Site, Ankara, , Turkey

Novartis Investigative Site, Edirne, , Turkey

Novartis Investigative Site, Hanoi, , Vietnam

Novartis Investigative Site, Hanoi, , Vietnam

Contact Details

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: